Human papillomavirus (HPV) has been implicated in the pathogenesis of anal carcinoma, which is increased in homosexual men. Little is known about the serologic response to HPV in normal or immunosuppressed men; therefore, HIV-infected and -uninfected homosexual men were screened for HPV-6 and -16 capsid antibodies. HIV-infected men had increased HPV DNA detection but did not significantly differ in the prevalence of serum HPV antibodies. HPV-6 DNA detection and the presence of anal warts were significantly correlated with serum antibody overall and in the HIV-infected subgroup. HPV-16 DNA detection was not significantly correlated with serum antibody overall or in either subgroup; however, HIV-infected men with high-grade anal squamous intraepithelial lesions were significantly more likely to have HPV-16 antibodies. HIV-infected men are able to generate an antibody response to HPV, and a lack of serum HPV antibodies cannot explain the increased HPV-associated disease seen in HIV-infected men.
Human papillomavirus (HPV) is the causative agent of genition of HPV-6 or -16 DNA as well as clinical status (presence of genital warts for HPV-6 and presence of SIL for HPV-16) tal warts and has been implicated in the pathogenesis of anal carcinomas [1, 2] . Epidemiologic studies have shown that ho- [8 -14] . We undertook the present study to describe the typespecific serologic responses toward HPV capsid antigens in mosexual men are at increased risk for infection with HPV, as manifested by genital warts, primarily of the anus [3 -6] , and men with and without HIV infection. anal carcinoma [4] . We have previously reported an increased risk for detection of HPV DNA and detection of high-grade
Materials and Methods anal squamous intraepithelial lesions (ASIL) in human immunodeficiency virus (HIV) -seropositive men, especially those
Study subjects. Between October 1989 and December 1995, with CD4 cell counts õ500/mL [7] . 895 homosexual or bisexual men aged 16-50 years were selected from persons presenting to the Seattle-King County Department Although unlikely to affect established ongoing productive of Public Health AIDS Prevention Project (Seattle) for HIV testing, infection, antibodies against HPV capsid proteins may be able counseling, and education. The demographic and behavioral charto prevent reinfection or reexpression with the same or similar acteristics, prevalence of HPV DNA, risk of developing high-grade HPV type. This may be of particular importance for HIV-ASIL, and relationships to HIV infection in this population have seropositive persons, most of whom have been previously exbeen previously reported [7] . Remaining sera were available for posed to HPV. Thus far, studies of serum antibody to HPV HPV serologic testing from 255 subjects (study group). These men capsids have focused on HPV seroprevalence in women, with differed from the 670 from whom sera were unavailable for testing no data currently available on the serologic response in immuin that a greater percentage of the study population was HIVnosuppressed persons. In women, many groups have observed seropositive (60.4% vs. 54.8%), although this difference was not an association between HPV-6 or -16 seropositivity and detecsignificant (P Å .12). Mean age, number of sex partners, age at first rectal intercourse, and history of sexually transmitted diseases did not differ between those tested and not tested for serologic evidence of HPV infection. Furthermore, while the prevalence of anal HPV-16 was similar in the groups, the subjects tested in this Presented in part: 14th Annual International Papillomavirus Conference, study were more likely than those who were not tested to have Quebec, July 1995 (abstract 34).
Informed consent was obtained from all human subjects. The study protocol anal HPV-6/11 DNA detected by polymerase chain reaction (PCR) was approved by the Institutional Review Board at the University of Washing-(59% vs. 36%; P õ.001).
ton.
Procedures and collection of specimen. Each subject under- As an alternative, a cutpoint for classifying subjects as HPVcells were present and were classified according to the Bethesda positive or -negative on the basis of their ELISA values was deterrecommendations (negative, atypia of uncertain significance, and mined by use of a population-based method of maximum likelilow-and high-grade ASIL) [15] .
hood. This cutpoint was determined by assuming that the distribuDetection and typing of HPV DNA. Samples were analyzed tion of the observed log ELISA values was a mixture of two by PCR by use of HPV L1 consensus primers with subsequent normal distributions and estimating the relevant parameters by the classification of PCR products by HPV type-specific oligonucleomethod of maximum likelihood [16] . By assuming that the log tides, specifically an HPV-6/11 mix and a separate HPV-16 probe ELISA values for HPV-negative subjects followed the estimated as described previously [7] . Primers PC04 and GH20 were used normal distribution with the smaller mean and that the log ELISA to prime the synthesis of a 256-bp fragment of the eukaryotic bvalues for HPV-positive subjects followed the estimated normal globin gene, and primers MY11 and MY09 were used to prime distribution with the larger mean, the cutpoint was chosen so that the synthesis of a 45-bp fragment of the HPV L1 gene. Each DNA the sensitivity and specificity resulting from these two estimated template sample was amplified twice. Controls containing K562 distributions was equal. The histogram of log ELISA values for cell line DNA and purified SiHa cell line DNA (HPV-16) were HPV-6, as well as the estimated normal distribution of these values tested with each run of 22 patient samples. After amplification, for seropositive and seronegative subjects, is shown in figure 1 . PCR products underwent electrophoresis, staining with ethidium For HPV-6, a cutpoint of 0.830 was obtained that gave a sensitivity bromide, and observation under UV illumination. Amplified samand specificity of 85%. (Sensitivity is defined as the percentage ples demonstrating the 250-bp b-globin fragment on a gel were of subjects in the upper curve who have ELISA values to the right considered to have sufficient numbers of eukaryotic cells present of the chosen cutpoint, whereas specificity is the percentage of for analysis for HPV types by dot-blot hybridization with HPVmen under the lower curve who have ELISA values to the left of 6/11 and -16 biotinylated probes by standard methods [7] . Consecthe cutpoint.) For HPV-16, a cutpoint of 0.261 was obtained that utive HPV-6/11 or -16 DNA positivity was defined as being posigave a sensitivity and specificity of 75%. These cutpoints were tive for the respective HPV DNA type at the same time as serologic very similar to those generated by assaying the sera from the testing and on the most recent HPV DNA test preceding the serosexually inexperienced women. By use of either cutpoint determilogic test.
nation, no significant differences were noted in the data analysis.
HPV-6 and -16 capture ELISA. The HPV-6 capture ELISA
The data presented used the cutpoint determined from the sexually was performed as described by Carter et al. [8] . The amounts of inexperienced women. monoclonal antibody and capsids used were predetermined by use x 2 values were calculated to assess the association between of positive control sera to maximize the signal and minimize the serology and other factors. Odds ratios (ORs) were calculated to background. After this determination, the amounts of these reassess the strength of these associations. When expected frequenagents did not vary when test population sera were assayed. Briefly, cies were õ5, one-sided Fisher's exact tests were performed. Manthe capture antibody was an anti-HPV-11 monoclonal antibody, tel-Haenszel x 2 and ORs were used to assess the relationship beH11b.2 (provided by N. Christensen, Pennsylvania State Medical tween serology and DNA detection by PCR when adjusting for Center, Hershey), which was diluted 1/800 in 0.1 M sodium careither HIV status or CD4 cell count. Multivariate logistic regresbonate (pH 9.5) buffer and allowed to attach overnight at room sion was used to test for independent associations between demotemperature to ELISA plates (Immulon 2; Dynatech Laboratories, graphic, clinical, and laboratory factors and HPV serology in both Chantilly, VA). Plates were washed and then blocked with blotto HIV-negative and -positive men. To assess which factors were (5% nonfat powdered milk, 0.15 M NaCl, 15 mM sodium azide) independently associated with HPV serology, forward stepwise plus 0.05% Tween 20 for 1 h at room temperature. HPV-6b L1 model-building methods, with an entry criterion of P õ .1, were capsids produced from recombinant vaccinia viruses were purified used. Four multivariate logistic regression models (one each for on cesium chloride gradients, diluted to 1/100 in PBS, added to HIV-negative and -positive men for both HPV-6 and -16 serology) the plates, and allowed to incubate at 37ЊC for 1 h. The plates were built in this fashion. were washed, human sera were diluted 1/100 in blotto and added For HIV-negative men, the factors included for evaluation in to the plates, and plates were incubated at 37ЊC for 1 h. The plates the stepwise forwards model building were age ú35, recent rewere washed, incubated with a 1/1000 dilution of goat anti-human ceptive anal intercourse, age of first receptive intercourse, ú50 IgG alkaline phosphatase-conjugated antibody (Boehringer lifetime sex partners, nonwhite race, history of intravenous drug Mannheim, Indianapolis) for 1 h, washed, and developed. For each use, history of anal warts, history of penile warts, history of gonosample, the median of three wells without capsids was taken and coccal urethritis, persistent HPV detected by PCR, any HPV DNA subtracted from the median of three wells with capsids. The HPVdetected by PCR, any anal dysplasia (ASIL) detected by cytology, 16 assay was performed as previously described by Carter et al.
warts detected on anal examination, low-grade anal cytology, and [14], using a monoclonal antibody to HPV-16, H16.V5 (provided high-grade anal cytology. In HIV-positive men, we added CD4 by N. Christensen), at a 1/2000 dilution and vaccinia-produced cell count as a continuous variable, CD4 cell count õ200, and HPV-16 L1 capsids that were cesium chloride-purified.
CD4 cell count õ500 to the list of potential independent risk Statistical methods. Cutpoints for the ELISA were determined by two methods. The first assayed a group of 64 women with no factors.
/ 9d31$$se14 07-01-97 11:27:07 jinfa UC: J Infect with than among those without antibody to HPV-6 capsids. or consecutive (previous and current) visits (HPV-6: OR, 1.6; Among HIV-seropositive men (table 2) , detection of anal HPV-CI, 0.9 -2.8; HPV-16: OR, 4.1; CI, 1.9 -9.6). In addition, HIV-6 DNA on one (OR, 2.9; CI, 1.3 -6.3) and on consecutive visits infected men were more likely than were those without HIV (OR, 3.2; CI, 1.5 -6.7) was associated with HPV-6 seropositivinfection to have anal warts present on examination (OR, 1.9; ity. Furthermore, among HIV-seropositive men, those with anal CI, 1.1 -3.3) and to have low-(OR, 1.4; CI, 0.8 -2.7) or highwarts present on examination were more likely to have antibodgrade ASIL on anal Pap smear (OR, 2.8; CI, 0.5 -27.7). Howies to HPV-6 than were those without such findings (OR, 3.2; ever, despite the fact that HIV-seropositive subjects were more CI, 1.4 -7.5). Mean CD4 cell count on the day of serologic likely to have anal HPV DNA detected, the prevalence of serum testing was not associated with HPV-6 serology (P Å .8). IgG antibodies to either HPV-6 (OR, 0.7; CI, 0.4 -1.2) or HPVSeropositivity to HPV-6 was seen in 21 (29%) of 72 men with 16 (OR, 0.8; CI, 0.5 -1.3) did not differ significantly among CD4 cell count ú500/mL, 19 (37%) of 51 men with CD4 cell those with and without HIV infection. In addition, there was count between 200 and 500/mL, and 6 (24%) of 25 men with no difference in the average ELISA values for HPV-6 (P CD4 cell count õ200/mL (P Å .9). Å .20) or -16 (P Å .50) by HIV status.
A multivariate analysis was performed with the parameters Associations with HPV-6 seropositivity. Overall in the unioutlined in Methods. For HIV-seronegative men, the multivarivariate analysis, HPV-6 seropositivity was associated (even ate analysis showed that a history of genital warts (OR, 3.2; after adjusting for detection of anal HPV-6 DNA) with the CI, 1.3 -8.5; P Å.02) and a history of urethritis caused by presence of anal warts (OR, 2.3; CI, 1.2 -4.5; P Å .005). Detecgonorrhea (OR, 4.0; CI, 1.4 -12.2; P Å .01) were independently tion of anal HPV-6 DNA by PCR on a single visit (OR, 2.2; associated with antibodies to HPV-6. A trend was noted be-CI, 1.2 -3.8; P Å .008) or consecutive visits (OR, 2.5; CI, tween the detection of HPV-6 DNA and antibodies to HPV-6 1.4 -4.3; P Å .001) was also associated with the presence of (OR, 2.1; CI, 0.8 -5.7; P Å .12). The optimal multivariate antibodies to HPV-6 (data not shown). However, the presence model for HIV-seropositive men demonstrated that anal warts of HPV-6 seropositivity was not significantly associated with seen on examination (OR, 2.9; CI, 1.1 -8.5; P Å.03) and the HIV status (P Å .15), age (P Å .06), and low-(P Å .4) or presence of HPV-6 DNA on consecutive visits (OR, 4.4; CI, high-grade ASIL (P Å .8).
1.8 -11.0; P Å.001) were independently associated with antiAmong HIV-seronegative men (table 2), HPV-6 seropositivity was associated with a history of gonococcal urethritis (OR, bodies to HPV-6.
/ 9d31$$se14 07-01-97 11:27:07 jinfa UC: J Infect Associations with HPV-16 seropositivity. Overall, seropos-A multivariate analysis using a model as outlined in Methods demonstrated for HIV-seronegative men that ú50 lifetime male itivity to HPV-16 capsids was associated with age ú35, (OR, 1.7; CI, 1.0 -2.8; P Å .04) and ú50 lifetime sex partners (OR, sex partners (OR, 3.8; CI, 1.6 -9.0; P Å .002) was significantly associated and age ú35 (OR, 2.0; CI, 0.8 -4.7; P Å .11) was 2.8; CI, 1.7 -4.8; P õ .001) but not with detection of anal HPV-16 DNA (P Å .50) or the presence of low-(P Å .6) or suggestive of an independent association with antibodies to HPV-16. For HIV-seropositive men, age at first receptive interhigh-grade ASIL (P Å .13, data not shown). In HIV-negative subjects, antibodies to HPV-16 were associated with age ú35 course (OR, 0.90; CI, 0.84 -0.96; P Å .003) and intravenous drug use (OR, 0.37; CI, 0.14 -0.92; P Å .04) were significantly (OR, 2.5; CI, 1.1 -5.6; P Å .03), ú50 lifetime partners (OR, 4.8; CI, 1.8 -9.5; P õ .001), history of intravenous drug use associated with the lack of antibodies to HPV-16. Furthermore, a CD4 cell count õ200 (OR, 0.43; CI, 0.15 -1.1; P Å .1) (OR, 7.6; CI, 1.9 -30.5; P Å .004), and a history of gonococcal urethritis (OR, 2.7; CI, 1.1 -6.5; P Å .02). Among HIV-infected was suggestive of an independent association with the lack of antibodies to HPV-16. The presence of high-grade ASIL was men, HPV-16 -seropositive subjects were more likely to have had initial anal intercourse at an earlier age (P Å .04) and to independently associated with the presence of antibodies to HPV-16 (OR, 5.7; CI, 1.0 -48.8; P Å .07). have ú50 lifetime sex partners (OR, 2.3; CI, 1.2 -4.5; P Å .02) than were those who were without antibodies to HPV-16. In the univariate analysis for both HIV-seronegative Discussion and -seropositive subjects, there was no significant association between HPV-16 -seropositive status and the presence of In this study of men who have sex with men, we found that HPV-16 DNA (P Å .8, P Å .4, respectively), the presence of the presence of antibodies to HPV-6 was associated with clinihigh-grade (P Å .2, P Å .3, respectively) or low-grade ASIL cal and laboratory evidence of HPV infection (presence of anal (P Å .8, P Å .6, respectively), or the average CD4 cell count warts and the detection of anal HPV-6 DNA), while prevalence (P Å .9, P Å .5, respectively). Seropositivity to HPV-16 was of antibodies to HPV-16 varied by demographic and behavioral seen in 33 (46%) of 72 men with CD4 cell counts ú500/mL, characteristics (older age and number of lifetime sex partners). 22 (43%) of 51 men with CD4 cell counts between 200 and Interestingly, the prevalence of antibody to both high-and low-500/mL, and 8 (32%) of 25 men with CD4 cell counts õ200/ risk types of HPV infection (HPV-16 and -6, respectively) was similar among those with and without HIV infection and did mL (P Å .3).
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07-01-97 11:27:07 jinfa UC: J Infect not significantly vary among HIV-seropositive men by CD4 of anal HPV-6/11 DNA at one or consecutive study visits and the presence of genital warts. This is the first study to closely cell count.
Cellular immune mechanisms are probably the most imexamine the relationship between detection of HPV-6/11 DNA and seropositivity to HPV-6 in men, and it is believed portant means of controlling established HPV infection. Prevalence of HPV infection and severity of HPV-associated disease that a stronger relationship would be found if the HPV DNA testing was restricted to detect only HPV-6. In addition, this is increased in patients with defects in cellular immunity, including HIV infection [7, 17 -24] . Furthermore, even though is the first demonstration in men of an association between the presence of genital warts and seropositivity to HPV-6 disease caused by HPV is increased or more severe in the HIV-infected patient, this study showed that the prevalence of capsids. We have previously screened for antibodies to HPV-6 capsids in 293 men and 236 women enrolled in a casehumoral antibodies to HPV-6 and -16 capsids is not influenced by HIV status. In the multivariate analysis, an association of control study of genital warts [8] and showed that HPV-6 seropositivity was associated with warts only among women. a low CD4 cell count (õ200) and the lack of serum HPV-16 antibodies was suggested, but the magnitude of this association
The men studied by Carter et al. [8] were predominately (96%) heterosexual, had relatively few lifetime sex partners (mean, was small (2.5-fold) and not significant (P Å .1). A larger study may demonstrate a significant association between severely Ç10), and most likely had penile rather than intraanal warts [25] . A small study (n Å 35) of patients attending a private immunosuppressed HIV-infected men and a lack of serum HPV antibodies, but this would not explain the increase in HPV practice dermatology clinic [9] demonstrated that all 12 women with genital warts had antibodies to HPV-6 capsids, DNA detection and HPV-associated disease seen at higher (ú200) CD4 cell counts [7] . It is unlikely that the presence whereas only 4 (16%) of 25 men were seropositive. This study by Greer et al. [9] excluded patients who were immunosupof HPV capsid antibodies in the serum have a major role in controlling established infection. It is more likely that the depressed or had anal warts. The increased sexual activity of the homosexual male population in this study or the location tected antibodies function to prevent reinfection or reexpression with the same or a similar HPV type.
of genital warts on a mucosal surface (anus) could explain the positive association seen here between antibodies to HPVThe strongest associations in both the univariate and multivariate analysis with HPV-6 seropositivity were the detection 6 capsids and the presence of genital warts.
/ 9d31$$se14 07-01-97 11:27:07 jinfa UC: J Infect
The associations between detection of anal HPV-6/11 DNA, HPV-6/11 DNA and disease state (anal warts), whereas the presence of HPV-16 capsid antibodies did not. the presence of genital warts, and HPV-6 capsid antibodies tended to be stronger in HIV-infected men. This is most likely due to the immunosuppressive effect of HIV that may allow
